Todd S. Thomson - 21 May 2026 Form 4 Insider Report for ACTUATE THERAPEUTICS, INC. (ACTU)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: ACTU
Reported as of: 21 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 May 2026, 16:14:24 UTC
Prior SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Paul Lytle, Attorney-in-Fact

Key filing fact

Todd S. Thomson filed Form 4 for ACTUATE THERAPEUTICS, INC. (ACTU) on 22 May 2026.

Key facts

This page summarizes Todd S. Thomson's Form 4 filing for ACTUATE THERAPEUTICS, INC. (ACTU).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 May 2026, 16:14.

Change

Previous filing in this sequence was filed on 18 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001225707 Primary reporting owner

THOMSON TODD S

Relationship: Director, 10%+ Owner
Address: C/O ACTUATE THERAPEUTICS, INC., 1751 RIVER RUN, SUITE 400, FORT WORTH
Signature: /s/ Paul Lytle, Attorney-in-Fact
Signature date: 22 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACTU transaction Derivative

Stock Options

Award

Transaction value
Shares: +15,000
Change %
Price: $0.000000^*
Shares after: 15,000
Date: 21 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $2.42
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Options will vest in full on the anniversary of the grant date.

Footnote F2

Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of Kairos Venture Investments, LLC ("KVI"), and serves on the board of directors (the "Board") of Actuate Therapeutics, Inc. ("Actuate"). Mr. Thomson has advised Actuate that he serves on the Board as a representative of certain funds managed and controlled by KVI (the "Kairos Funds") and because Mr. Thomson serves on the Board as a representative of the Kairos Funds, certain of the Kairos Funds have a right to an economic interest in the securities of Actuate granted to Mr. Thomson in respect of his Board position and such Kairos Funds are entitled to an indirect pecuniary interest in such securities, including the Stock Options reported on this Form 4.